What a Cardiologist Actually Checks in a Man Over 40.

Most men who have a heart attack before age 55 had a normal cholesterol panel at their last physical. The standard annual visit was not designed to catch the things that actually kill men in midlife, and a preventive cardiology evaluation is a different instrument entirely.

The Mechanism

Atherosclerosis is not a cholesterol problem. It is a lipoprotein particle problem. The distinction matters because standard lipid panels report cholesterol mass, not particle number, and those two values diverge more than most physicians acknowledge in routine practice.

Here is the physics. LDL particles vary in size. A man can have an LDL cholesterol of 110 mg/dL, which looks acceptable on a standard panel, while carrying 1,600 nmol/L of LDL particles, a number consistent with a significantly elevated atherogenic burden. Small, dense LDL particles transit the endothelium more readily than large buoyant ones, oxidize faster once inside the arterial wall, and drive the inflammatory cascade that produces the fibrous cap over a lipid core that we call a plaque. Each particle that crosses the endothelium carries roughly the same atherogenic potential regardless of how much cholesterol it holds. So counting particles, not mass, gives the more accurate signal.

ApoB is a single protein: one molecule per atherogenic lipoprotein particle, whether that particle is LDL, VLDL, IDL, or Lp(a). An ApoB level measures total atherogenic particle burden in a single number. This is what a cardiologist actually wants to know.

Simultaneously, inflammation amplifies the process. Oxidized LDL triggers macrophage recruitment. Macrophages become foam cells. Foam cells accumulate, the fibrous cap thins, and the plaque becomes vulnerable to rupture. Elevated high-sensitivity C-reactive protein is a measurable signal of that inflammatory environment. It is not a cause of atherosclerosis, but it marks a biological state in which plaques are more likely to rupture.

Blood pressure adds a second injury mechanism running in parallel. Shear stress from chronically elevated pressure damages the endothelial glycocalyx, the protective lining of the vessel wall, accelerating lipid entry and foam cell formation at branch points in the coronary tree. A man whose blood pressure reads 126/82 in a clinic waiting room may spend the hours between 6 a.m. and 10 a.m., the peak cardiovascular risk window, running 145/94 at work. That discordance, called masked hypertension, is invisible to office-based measurement.

Insulin resistance feeds both mechanisms. When skeletal muscle cells resist insulin signaling, the liver compensates by producing more VLDL, which downstream increases small dense LDL particle number. Insulin resistance also promotes systemic inflammation through increased production of pro-inflammatory cytokines. A man can be non-diabetic with a normal fasting glucose and still carry significant insulin resistance that is driving his lipid and inflammatory profile in the wrong direction. Fasting insulin exposes this.

What the Evidence Shows

ApoB versus LDL: The National Lipid Association published position statements in 2022 affirming ApoB as a superior marker of residual cardiovascular risk compared with LDL-C, particularly in the setting of hypertriglyceridemia or metabolic syndrome. The INTERHEART study, spanning 52 countries and published in the Lancet by Yusuf and colleagues in 2004, found that the ApoB-to-ApoA1 ratio had stronger population-level association with myocardial infarction risk than any standard lipid fraction.

Lp(a): Lipoprotein(a) is a distinct lipoprotein particle: an LDL-like core with an additional apolipoprotein(a) protein attached. Its plasma concentration is 80 to 90 percent determined by genetics and does not respond meaningfully to lifestyle change. A 2022 analysis published in the European Heart Journal, drawing on UK Biobank data of over 400,000 participants, found that individuals with Lp(a) above 150 nmol/L (roughly 70 mg/dL) had a 3- to 5-fold higher risk of myocardial infarction compared with those in the lowest quintile, independent of LDL. Because Lp(a) levels are set at birth and do not change substantially over a lifetime, the European Society of Cardiology recommends measuring it at least once in every adult. Many men over 40 have never had this test.

hsCRP and the JUPITER trial: The JUPITER trial (Justification for the Use of Statins in Prevention, published in the New England Journal of Medicine in 2008 by Ridker et al.) enrolled 17,802 apparently healthy individuals with LDL below 130 mg/dL but hsCRP of 2.0 mg/L or higher. Rosuvastatin therapy in this elevated-hsCRP group reduced the primary endpoint of major cardiovascular events by 44 percent and all-cause mortality by 20 percent compared with placebo. The trial was stopped early at a median follow-up of 1.9 years because the benefit was considered sufficiently demonstrated. This is the evidence base for using hsCRP to reclassify men who look low-risk by LDL alone.

Coronary artery calcium scoring: The MESA trial (Multi-Ethnic Study of Atherosclerosis), a prospective cohort study following over 6,800 participants, established that CAC scoring significantly reclassifies cardiovascular risk in individuals classified as intermediate risk by traditional calculators. Among men classified as intermediate risk by Framingham score, those with a CAC score of zero had event rates comparable to low-risk individuals, while those with CAC scores above 300 had event rates comparable to high-risk individuals. The 2019 ACC/AHA Primary Prevention Guidelines incorporated CAC scoring as a Class IIa recommendation to guide statin therapy decisions in patients where the benefit is uncertain.

The Agatston score is the standard unit. A score of zero means no calcified plaque is detectable and confers a genuinely low risk: MESA data showed that a CAC of zero in an intermediate-risk individual yielded a 10-year major cardiovascular event rate of approximately 3 percent, below the threshold where most guidelines recommend statin therapy. Scores from 1 to 100 indicate mild plaque burden. Scores from 101 to 400 indicate moderate burden. Scores above 400 indicate severe calcified plaque and warrant aggressive risk factor management regardless of what the standard lipid panel shows.

The Pooled Cohort Equations problem: The PCE, the risk calculator embedded in the 2013 ACC/AHA guidelines, was developed from cohorts that are now decades old. It performs reasonably in non-Hispanic White and African American populations, but it underestimates risk in South Asian men and has not been well validated in Hispanic or East Asian populations. It also underestimates lifetime risk in younger intermediate-risk individuals because it calculates 10-year risk, which at age 42 can appear reassuringly low even in a man with significant subclinical plaque. A 42-year-old man with a PCE-derived 10-year risk of 7.5 percent may have a lifetime risk exceeding 40 percent. CAC scoring, Lp(a), and hsCRP all provide information the PCE cannot incorporate and that can substantially shift the clinical decision.

USPSTF 2022 statin recommendations: The U.S. Preventive Services Task Force 2022 update recommends initiating a statin for primary prevention in adults aged 21 to 75 who have one or more CVD risk factors (dyslipidemia, hypertension, diabetes, or smoking) and an estimated 10-year CVD event risk of 10 percent or greater. For individuals with a 10-year risk between 7.5 and 10 percent, the USPSTF grades the recommendation as “C,” meaning individual clinical judgment applies. This is precisely the intermediate-risk zone where CAC scoring provides the most decision-relevant information.

Masked hypertension: A meta-analysis published in Hypertension in 2019 (Banegas et al.) estimated that masked hypertension, defined as normal office blood pressure with elevated ambulatory daytime blood pressure, affects approximately 15 to 30 percent of the general adult population. Among working-age men, prevalence is higher because office measurements capture the post-commute, waiting-room state rather than the sustained pressure during occupational stress. Ambulatory blood pressure monitoring, a 24-hour wearable cuff recording readings every 15 to 30 minutes, is the only method that detects this phenotype. The prognostic significance of masked hypertension is equivalent to sustained hypertension in terms of left ventricular hypertrophy and cardiovascular event rates.

Testosterone and cardiovascular risk: The evidence base here is less settled, which is worth stating directly. The TRAVERSE trial (published in the New England Journal of Medicine in 2023), a randomized controlled trial of 5,246 men with hypogonadism and pre-existing or high risk of cardiovascular disease, found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events over a median follow-up of 22 months. This partially resolved prior safety concerns raised by a 2010 study (Basaria et al., NEJM) that was stopped early due to an apparent cardiovascular signal. However, TRAVERSE enrolled men with established disease, not healthy men with borderline testosterone levels, so generalization to primary prevention requires caution. The connection between low free testosterone and metabolic syndrome, insulin resistance, and visceral adiposity is well-documented in observational data; the causal direction and clinical implications remain under investigation.

Exercise Capacity: The Sixth Vital Sign

Cardiorespiratory fitness is among the strongest independent predictors of cardiovascular mortality in men, yet it is rarely quantified at the annual cardiology visit. The reason is practical: a treadmill or cycle ergometer test takes time, requires equipment, and is not reimbursed as a screening procedure in most clinical settings. But the absence of formal testing does not make exercise capacity unmeasurable — estimated metabolic equivalents from a structured clinical history carry meaningful prognostic weight and belong in every cardiovascular risk assessment.

The landmark study on this question comes from Myers and colleagues, published in the New England Journal of Medicine in 2002. They analyzed exercise test data from 6,213 men referred to cardiology clinics and found that exercise capacity was the strongest predictor of all-cause mortality — stronger than any traditional cardiovascular risk factor including ejection fraction, hypertension, diabetes, and smoking status. Each 1-MET increment in peak exercise capacity was associated with a 12% reduction in all-cause mortality after adjustment for covariates. The association held across the full spectrum from low to high exercise capacity with no apparent ceiling in the range studied.

Kokkinos and colleagues extended this finding in a 2010 Circulation analysis of 9,777 men undergoing treadmill testing at the Veterans Affairs Medical Center in Washington, D.C. Peak exercise capacity independently predicted all-cause mortality after adjustment for age, body mass index, smoking, hypertension, diabetes, and medication use. The gradient was continuous: men achieving 8 METs or more had substantially lower mortality than those achieving fewer than 5 METs. In men aged 40 to 55 without established coronary disease, achieving at least 10 METs on standard Bruce protocol treadmill testing is associated with low cardiovascular mortality in the intermediate term.

The clinical implication for the annual cardiovascular review: estimated exercise capacity belongs in the physician note alongside ApoB, blood pressure, and fasting insulin. A man who reports completing 45 minutes of continuous moderate-intensity exercise, maintaining a conversation during brisk walking, or reaching near-age-predicted maximum heart rate without stopping is providing clinically meaningful information. A man who describes significant exertional limitation, dyspnea at low workloads, or inability to climb two flights of stairs without stopping is flagging a functional impairment that warrants formal treadmill evaluation regardless of whether resting biomarkers appear normal. The CAC score and ApoB describe the burden of atherosclerotic disease; exercise capacity describes the functional reserve of the cardiovascular system. Both belong in a complete risk picture.

What to Do This Week

1. Get an ApoB and Lp(a) added to your next blood draw. These are not standard on routine panels and require a specific order. If your physician does not routinely order them, ask directly. ApoB should ideally be drawn fasting. Lp(a) does not require fasting and only needs to be measured once in most cases because it is genetically stable.

2. Add an hsCRP to that same draw. It requires no additional preparation. A level above 2.0 mg/L in the context of otherwise borderline lipid values is the clinical profile the JUPITER trial identified as benefiting from statin therapy in primary prevention.

3. Check your blood pressure at home, at different times of day. Buy a validated upper-arm cuff, not a wrist device. Measure in the morning before coffee, before physical activity, and again in the evening. Track readings across five to seven days and bring the log to your next appointment. Office readings alone are insufficient for men in physically demanding or high-stress occupations.

4. Ask your physician whether CAC scoring makes sense for your risk profile. If your 10-year PCE risk is somewhere between 5 and 20 percent, you are in the range where CAC scoring is most decision-relevant. The test is a low-dose CT scan of the chest without contrast, takes approximately 10 minutes, and carries a radiation dose roughly equivalent to a mammogram. It is not universally covered by insurance, but out-of-pocket cost typically runs $75 to $200.

5. Request a fasting insulin level. It is not on standard metabolic panels. A fasting insulin above 10 to 15 mcIU/mL in a non-diabetic man with a normal fasting glucose is a signal of early insulin resistance, which drives atherogenic dyslipidemia and inflammation independent of body weight. This result reframes the conversation about how aggressive lipid and blood pressure management needs to be.

A preventive cardiology visit is not a reassurance visit. It is a measurement visit. What it produces is a clearer picture of the biological state of a man’s arteries and metabolic system at a point in time when the trajectory can still be altered, before the first event that usually prompts the referral in the first place.